🔬 This process assembles RNA fragments using non-engineered T4 RNA ligase 2, making it suitable for clinical therapy pipelines.
📊 HPLC analysis shows improved purity in their sgRNAs compared to market vendors. The method promises significant advancements in gene editing.
Introduction:
The article discusses a novel chemo-enzymatic method developed by researchers at F. Hoffmann-La Roche and Genentech for synthesizing synthetic oligonucleotide single guide RNA (sgRNA). This method significantly enhances both yield and purity, crucial aspects for applications in gene editing and cell therapy utilizing CRISPR-Cas technology.
- The new chemo-enzymatic method increases sgRNA purity by 10-15% and yield by three- to four-fold compared to traditional methods.
- The process utilizes T4 RNA ligase 2 to assemble RNA fragments derived from standard solid-phase chemistry.
- Aqueous buffer preparation is critical, consisting of Tris-HCl, magnesium chloride, dithiothreitol, and ATP at pH 7.2.
- The method has successfully produced multiple sgRNAs intended for CRISPR-Cas systems, achieving superior purity compared to commercial sgRNA sources.
- Downstream processes include chromatographic purification and ultrafiltration, making the synthesized sgRNAs suitable for clinical applications.
Conclusion:
The reported chemo-enzymatic method not only improves sgRNA purity and yield but also enhances its applicability in CRISPR-Cas gene editing for cell therapy. The findings indicate that this approach is readily adaptable for broader research applications, marking a significant advancement in the field of synthetic biology and therapeutic development.
